Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apoptosis inhibitor 5 pseudogene 1 (API5P1) is classified as a pseudogene in the human genome, meaning that it is homologous to a functional gene (in this case, API5) but does not encode a functional protein itself[7][1][5]. Pseudogenes can arise through gene duplication or retrotransposition events and typically lack biological activity. API5P1 is listed as a pseudogene by several authoritative resources, including the HUGO Gene Nomenclature Committee (HGNC), and has the locus type "pseudogene"[7]. There is no evidence that API5P1 plays a direct role in disease, is druggable, or acts as a receptor, enzyme, transcription factor, or other conventional molecular target in therapeutic contexts. Important Distinction: Confusion may arise because the functional gene API5 (Apoptosis inhibitor 5) is a protein-coding gene involved in apoptosis inhibition and associated with certain cancers[8][2][3]. However, API5P1 refers specifically to the non-functional pseudogene copy, and not to the active therapeutic target API5. For drug discovery or mechanistic biology interests, refer to "Apoptosis inhibitor 5" (API5), not API5P1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apoptosis inhibitor 5 pseudogene 1 (API5P1).